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ABSTRACT The molecular defects in two congenital ab-
normal fibrinogens, Umuiden and Nimegen, were determined
by sequence analysis of genomic DNA amplified by the polym-
erase chain reaction. Both fibrinogens were heterozygous,
UImuiden having a BfiArg14-)Cys substitution and Nolmegen
having a BfIArg44--Cys substitution. Clotting induced by
thrombin or Reptilase was impaired in both fibrinogens,
indicating defective fibrin polymerization. Immunoblot anal-
ysis of both purified fibrinogens demonstrated that some of the
abnormal molecules were linked by disulfide bonds to albumin.
In addition, abnormal high molecular weight fibrinogen com-
plexes with Mrs between 600,000 and 700,000 were present.
Fibrinogen-albumin and high molecular weight complexes
were also detected in the patients' plasmas. Quantative analysis
demonstrated that of the total plasma fibrinogen in the U-
muliden patient, 20% was linked to albumin and 10% was
present as high molecular weight complexes. In plasma Ni-
jmegen, 13% was linked to albumin and 15% was present as
high molecular weight complexes. These results demonstrate
that the additional abnormal cysteine in fibrinogens Umuiden
and Nimegen resulted in the formation of disulfide-linked
complexes with other proteins, predominantly albumin. We
also found that a significant fraction ofthe abnormal fibrinogen
molecules contained free sulfhydryl groups. These findings
complicate interpretation of functional studies of these altered
fibrinogens.
The fibrinogen molecule is a dimer of three polypeptides, Aa,
Bf3, and y, linked together by 29 disulfide bonds (1). During
coagulation fibrinogen is converted to an insoluble fibrin
matrix by thrombin-catalyzed removal of fibrinopeptides
from the Aa and the BP chains. Congenital dysfibrinogene-
mia is a disorder in which a fibrinogen structural abnormality
results in altered functional characteristics. A number of
abnormal fibrinogens have been described (2), some associ-
ated with bleeding disorders and some associated with throm-
bosis. The structural defects for -75 cases are known, with
21 cases of arginine substituted by cysteine-14 cases of
AaArg,6-+Cys, 2 cases of BPArg14--Cys, and 5 cases of
yArg75-Cys. For a few cases the consequences of an
additional cysteine have been studied. For homozygous
fibrinogen Metz (3) and heterozygous fibrinogens Kawaguchi
and Osaka I (4), it has been reported that AaCys16 partici-
pates in an intramolecular disulfide bond between two ab-
normal Aa chains. Consequently, in heterozygous individu-
als, abnormal molecules are homodimers-that is, both Aa
chains in one fibrinogen molecule are abnormal. In contrast,
analysis of another heterozygous AaCys16 mutant, Stony
Brook I (5), indicated that heterodimers are present. Ho-
modimers of abnormal chains have been postulated for the
two heterozygous cases ofBfArg14-*Cys, Christchurch II (6)
and Seattle I (7). The additional cysteine in heterozygous
fibrinogen Osaka II (8), yArg275--Cys, was linked to a
cysteine molecule. Free sulfhydryl groups have not been
detected in these abnormal fibrinogens (3-5, 7, 8).
This report describes the structural defects in two fibrin-
ogens isolated from patients suffering from thrombophilia.
These are fibrinogen IJmuiden, Bf3Arg14--Cys, and fibrino-
gen Nijmegen, B.3Arg44-Cys. We found that these abnormal
fibrinogens circulate as disulfide-linked fibrinogen-albumin
complexes, as disulfide-linked high molecular weight fibrin-
ogen complexes, and as molecules with free sulfhydryl
groups.
MATERIALS AND METHODS
Materials. Unspecified materials were obtained from
sources previously described (9). Crotalus atrox venom,
DNA grade (A-6013), and ultra-low-gelling (A-5030) agarose
were from Sigma. CH-activated Sepharose 4B, gelatin-
Sepharose 4B, precast polyacrylamide gradient gels, SDS/
PAGE molecular weight calibration kit, and an FPLC system
with a Superose 12 column were obtained from Pharmacia.
Rabbit anti-human albumin antiserum was purchased from
Behringwerke AG, horseradish peroxidase (HRP) conjugat-
ed-goat anti-human albumin and goat anti-rabbit immuno-
globulins were from Nordic, and rabbit anti-human fibrino-
gen By3 1-42 was from IMCO (Stockholm). A pool of rabbit
anti-human fibrinogen IgGs was prepared as described (10).
The monoclonal anti-fibrinogen antibody (11) conjugated
with HRP (Y18/HRP) was a generous gift of W. Nieuwen-
huizen (IVVO-TNO, Gaubius Laboratory). Nitrocellulose
was from Schleicher & Schull (Dassel, F.R.G.). Polystyrene
microtiter plates (Immulon) were from Greiner (Alphen a/d
Rijn, The Netherlands). Ellman's reagent [5,5'-dithiobis(2-
nitrobenzoic acid) (DTNB)] and 4-chloro-1-naphthol were
from Aldrich. Phosphate-buffered saline (PBS, pH 7.4) con-
tained 0.15 M NaCI, 0.01 M Na2HPO4, and 1.6 mM KH2PO4.
Coagulation Studies. Blood was collected and plasma was
prepared as described (12). Thrombin and Reptilase (Boeh-
ringer Mannheim) clotting times were performed as described
(13). The plasma concentration of fibrinogen was determined
functionally (14) and immunologically (15). Release of FpA
and FpB from purified fibrinogen was determined as de-
Abbreviations: HRP, horseradish peroxidase; HMW, high molecular
weight; LMW, low molecular weight; DTNB, 5,5'-dithiobis(2-
nitrobenzoic acid).
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scribed (13). Coagulation profiles of purified fibrinogen dia-
lyzed against 0.1 M Tris HCl (pH 7.5) were determined by
measuring the increase in absorbance at 350 nm (9).
Protein Purification. Fibrinogen was purified from plasma
(16), contaminating fibronectin was removed by adsorption
to a gelatin-Sepharose column (19), and the fibrinogen was
concentrated by precipitation in 50% saturated (NH4)2SO4.
The precipitate was dissolved in 0.15 M NaCl, dialyzed
against this solution for 24 hr at 40C, and stored at -200C.
Rabbit anti-human albumin IgGs were purified from serum by
precipitation with 18% Na2SO4 (17), and the precipitate was
dissolved in and dialyzed against distilled water for 24 hr at
40C and lyophilized.
SDS/PAGE. SDS/PAGE was performed on 5-25% gradi-
ent gels according to Laemmli (18) or on 2-16% precast gels
using an electrophoresis buffer of 0.04 M Tris/0.02 M sodium
acetate/0.002 M EDTA/0.02% SDS, pH 7.4, and a sample
buffer of 0.01 M Tris.HCI/0.001 M EDTA/1% SDS, pH 8.0.
Molecular weights were estimated using a low molecular
weight (LMW) calibration kit and a mixture of monoclonal
IgM, fibronectin [eluted from gelatin-Sepharose (19)], and
fibrinogen with molecular weights of 900,000, 450,000, and
340,000, respectively.
Immunoblot Analysis. SDS/PAGE gels were electroblotted
onto nitrocellulose (20). Intact proteins and C. atrox venom
digests were transferred to 0.45-pum and 0.1-pum nitrocellu-
lose sheets, respectively. The sheets were incubated with
0.01 M Tris HC1, pH 7.4/0.15 M NaCI/0.5% gelatin/0.05%
Tween 80 for 2 hr. Antibodies were diluted in 0.01 M
Tris HCI, pH 7.4/0.15 M NaCI/0.05% Tween 80 and cross-
reacting bands were visualized with 4-chloro-1-naphthol (21).
C. atrox Venom Digestions. Fibrinogen was dialyzed against
0.05 M Tris HCI, pH 7.5/0.1 M NaCI/5 mM EDTA, and the
concentration was adjusted to 2 mg/ml. Lyophilized venom
was dissolved in this buffer to 0.1 mg/ml and 5 p.l was added
to 0.5 ml of fibrinogen. The sample was incubated for 1 hr at
37°C and the reaction was stopped by adding an equal volume
of 0.1 M Tris HCI, pH 6.8/2% SDS/8 M urea, followed by
boiling for 5 min. When reducing disulfide bonds, 5% (vol/
vol) 2-mercaptoethanol was added before boiling.
Puriflication of Fibrinogen-Albumin Complexes. Purified
rabbit anti-human albumin IgGs were immobilized to CH-
activated Sepharose 4B following the manufacturer's guide-
lines. The amount of IgG coupled was :3 mg/ml of wet gel.
The immunoadsorbent was packed in a column (bed volume,
2 ml) and equilibrated with 6 mM disodium tetraborate/0.2 M
boric acid/5 mM EDTA, pH 7.4. Purified fibrinogen was
diluted to 0.5 mg/ml with borate buffer, and 5 ml was applied
to the column. The column was washed with 25 ml of borate
buffer, followed by 10 ml of borate buffer containing 1 M
NaCl to elute nonspecifically bound protein. Albumin com-
plexes were eluted with borate buffer containing 8 M urea,
and fractions containing protein were pooled, dialyzed
against distilled water for 16 hr at 4°C, lyophilized, and
dissolved in PBS to 0.1 mg/ml.
Enzyme Immunoassays. Microtiter plate wells were incu-
bated with 0.12 ml of rabbit anti-fibrinogen IgGs (20 pug/ml)
for 16 hr at 4°C and washed three times with PBS and 0.05%
Tween 20 (PBS/Tween). Samples (0.1 ml) diluted in PBS/
Tween were added, incubated for 1 hr at room temperature,
and the wells were washed as above. Bound fibrinogen was
measured by incubation for 1 hr at room temperature with 0.1
ml of rabbit anti-fibrinogen/HRP (10). Bound fibrinogen-
albumin complexes were measured by incubating with 0.1 ml
of goat anti-albumin/HRP for 1 hr at room temperature. The
wells were washed and bound HRP was quantitated by
incubation with 0.2 ml of substrate solution containing H202
and 3,3',5,5'-tetramethylbenzidine (22). After 30 min 50 p.l of
2 M H2SO4 was added and the absorbance at 450 nm
measured on a Titertek Multiscan.
Gel Filtration of Plasma. Plasma (0.25 ml) was diluted with
PBS (1:5) and applied to a FPLC Superose 12 column
equilibrated with PBS. Fractions were assayed for fibrinogen
and/or fibrinogen-albumin complexes using the enzyme im-
munoassay described above.
Titration ofFree Sulfhydryl Groups. Free sulfhydryl groups
in fibrinogen were determined using DTNB (23) in the
presence of urea (24). Purified fibrinogen was dissolved to 10
mg/ml in 0.05 M Tris HCl, pH 8.2/1 mM EDTA/8 M urea.
Five microliters of 10 mM DTNB was added to 0.5 ml of
fibrinogen and the sample was incubated for 10 min at room
temperature. The absorbance at 412 nm was measured and
reactive sulfhydryls were determined from the molar extinc-
tion coefficient = 13,600 M-lcm-1 (23).
DNA Amplification and Sequence Analysis. Genomic DNA
was isolated from blood cells (25). Primers l3a (5'-
GGTGTTGGAATAGTTACATTCC-3') and f8lb (5'-AT-
CAGTGCACCCACCAAGTCTGGG-3') amplified the DNA
coding for amino acids B,8 9-72. Amplification by PCR (26)
was performed in 100 pL. containing 1 pug ofgenomic DNA, 0.2
mM (each) dATP, dCTP, dGTP, and dTTP, 0.3 pug (each) of
primer in 10 mM Tris-HCI (pH 8.3) at 250C, 50 mM KCI, 3.0
mM MgCl2, and 0.001% gelatin. The samples were heated at
94°C for 4 min, 2 units of Taq DNA polymerase (Perkin-
Elmer/Cetus) was added, and the samples were incubated for
30 cycles of 1 min at 94°C, 0.5 min at 58°C, and 1.5 min at
72°C. Amplified DNA was precipitated with ethanol, dried,
dissolved in 20 p.1 of distilled water, and run on a 1.0%
(wt/vol) ultra-low-gelling agarose gel. The band with the size
predicted by the genomic sequence (27) was excised in 20
p.1 and heated to 55°C. One microliter of the melted agarose
was mixed with 1 p.1 of primer, pla (60 ng), and 2 p.l of Sx
annealing buffer (T7 sequence kit, Pharmacia), and the vol-
ume was brought up to 14 p.l with distilled water. The mixture
was heated to 95°C for 3 min and immediately put on ice.
Labeling (5 min) and termination (10 min) reactions were
performed using the T7 DNA sequencing kit as specified by
the manufacturer.
RESULTS
Coagulation Studies. The thrombin clotting times for
plasma IJmuiden (25.0 s) and Nijmegen (20.2 s) and the
Reptilase clotting times (26.0 s and 22.7 s, respectively) were
slightly prolonged compared to normal plasma (18.5 s for
thrombin and 20.0 s for Reptilase). The functionally deter-
mined fibrinogen concentration in plasma IJmuiden (0.9
mg/ml) and Nijmegen (1.2 mg/ml) was less than half that
determined immunologically (2.7 mg/ml and 3.5 mg/ml,
respectively). Clotting of purified fibrinogen induced by
either enzyme was impaired for both abnormal fibrinogens.
Thrombin-catalyzed release of FpB (B,8 chain residues 1-14)
from fibrinogen IJmuiden was half that of normal fibrinogen.
All other FpA and FpB release from either abnormal fibrin-
ogen with either protease was normal.
DNA Sequence Analysis. Since FpB release from fibrinogen
IJmuiden was abnormal, we amplified the DNA from exon II
of the B,8 chain, which codes for amino acids 9-72. In
addition to this segment, we also amplified Nijmegen DNA
encoding domains associated with abnormal clotting. DNA
sequence analysis (Fig. 1) demonstrated that the amplified BB
fragment from fibrinogen IJmuiden had a single base substi-
tution in the codon for Arg14 (CGT), changing this to the
codon for Cys (TGT). The corresponding BB gene fragment
from fibrinogen Nijmegen had a similar mutation, changing
the codon for Arg44 (CGT) to Cys (TGT). No other changes
were found. Direct sequence determination of the amplified
fragments showed the normal and the abnormal sequence,
indicating that these patients are heterozygous.
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FIG. 1. DNA sequence analysis of the amplified B,8 gene frag-
ments. Direct sequence analysis of amplified fragments demon-
strated heterozygous mutations at the positions indicated by the
arrowheads. In both cases C was substituted by T.
Analysis of Fibrinogen Cleavage with C. atrox Venom. C.
atrox venom cleaves the BP chain of fibrinogen between
amino acids 42 and 43 (28). When purified normal fibrinogen
was digested with venom and analyzed on immunoblots
developed with a rabbit antibody to BP 1-42, two crossre-
acting bands were seen, one at the top of the gel and a second
with Mr 6000 (Fig. 2C, lane 3). As undigested samples
contained only a crossreacting band at the top of the gel (Fig.
2D, lane 3), the two bands found after venom digestion are
probably residual intact fibrinogen and BP 1-42. Immunoblot
analysis of purified fibrinogen Nijmegen (BpArg44-Cys)
with anti-Bf8 1-42 demonstrated that after incubation with C.
atrox venom, an increased amount of fibrinogen Nijmegen
remained intact (Fig. 2C, lane 1), indicating that the venom
did not efficiently cleave the abnormal chain. A reduced
amount of the species with Mr 6000 was present as
expected if only the normal BPB chain was cleaved. SDS/
PAGE analysis of reduced samples confirmed that approxi-
mately half of the Bf3 chains in fibrinogen Nijmegen remained
intact after incubation with C. atrox venom (data not shown).
When purified fibrinogen IJmuiden was digested with
venom and analyzed by immunoblotting with antibody to BP
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FIG. 2. Immunoblot analysis of C. atrox digests of fibrinogen (A
and C) and intact fibrinogen (B and D). Samples of fibrinogen
Nijmegen (lanes 1), fibrinogen UImuiden (lanes 2), and normal
fibrinogen (lanes 3) were electrophoresed on a 5-25% polyacryl-
amide gradient/SDS gel. Proteins were blotted onto nitrocellulose
and developed with goat anti-albumin/HRP (A and B) or with rabbit
anti-Ba 1-42 followed by goat anti-rabbit IgG/HRP (C and D).
Molecular weights are given as Mr x 10-3.
1-42, four crossreacting species were found, as shown in Fig.
2C, lane 2. Two of these were present in normal fibrinogen
(Fig. 2C, lane 3), although the band representing residual
fibrinogen was more intense in fibrinogen IJmuiden than in
normal fibrinogen, indicating that the snake venom activity
was somewhat inhibited by the IJmuiden mutation. The
remaining two species with Mrs 14,000 and 68,000 (Fig. 2C,
lane 2) were not present in normal fibrinogen digests. SDS/
PAGE analysis of reduced fibrinogen IJmuiden samples
showed no bands in addition to those seen with normal
reduced fibrinogen (data not shown). These results suggest
that some of the Bf3 1-42 peptide in fibrinogen IJmuiden was
linked to other proteins or peptides by disulfide bonds. The
species with Mr 14,000 is probably BJ3 1-42 dimer, a
product previously suggested for two other BpArg14--Cys
substitutions in abnormal fibrinogens Christchurch 11 (6) and
Seattle I (7).
Immunoblot Analysis with Antibodies to Human Albumin.
To determine whether the additional IJmuiden band with Mr
68,000 was due to complex formation with albumin, as
described for an antithrombin III variant (29), we prepared
blots with unreduced samples and developed these with
anti-albumin/HRP. We also examined fibrinogen Nijmegen
for the presence of albumin complexes. Venom digests of
fibrinogen IJmuiden (Fig. 2A, lane 2) contained two anti-
albumin crossreacting species. One that remained at the top
of the gel was also present with undigested fibrinogen IJ-
muiden (Fig. 2B, lane 2). The second had Mr 68,000. Since
this species also reacted with anti-Big 1-42, it is most likely
a complex of albumin and Bf3 1-42. Venom digests of
fibrinogen Nijmegen contained one species at the top of the
gel that reacted with the anti-albumin antibodies (Fig. 2A and
B, lane 1), indicating that fibrinogen Nijmegen is also linked
to albumin. Normal fibrinogen samples did not react with the
anti-albumin antibodies (Fig. 2 A and B, lane 3). Immunoblot
analysis of reduced fibrinogen IJmuiden and fibrinogen Nij-
megen samples showed a single anti-albumin crossreacting
species with Mr 67,000, the same as the albumin band in the
molecular weight calibration markers; reduced normal fibrin-
ogen did not react with the anti-albumin antibodies (data not
shown). These results are consistent with the presence of
disulfide-linked albumin-fibrinogen complexes in fibrinogen
Nijmegen and fibrinogen IJmuiden. This is also consistent
with the observation that SDS/PAGE analysis of reduced
abnormal fibrinogen samples contained no abnormal bands
because albumin and the Aa chain of fibrinogen comigrate
under these conditions.
Analysis of Intact Fibrinogen and Larger Complexes. Puri-
fied fibrinogen samples were analyzed on 2-16%b gradient
SDS/PAGE gels stained with Coomassie blue. Normal fi-
brinogen (Fig. 3A, lane 3) contained two species previously
shown (30, 31) to be intact fibrinogen [high molecular weight
(HMW) Fbg, Mr = 340,000] and fibrinogen with a partially
degraded Aa chain (LMW Fbg, Mr = 300,000). These two
species were present in both abnormal fibrinogens. In addi-
tion, each abnormal fibrinogen contained three minor spe-
cies-one with Mr 400,000 and two with Mrs between
600,000 and 700,000 (Fig. 3A, lanes 1 and 2). Immunoblots
prepared from similar gels and developed with a monoclonal
anti-fibrinogen antibody (Fig. 3B) demonstrated that these
minor species contained fibrinogen. Two additional crossre-
acting species of Mr = 360,000 and Mr between 600,000 and
700,000 were present. Similar blots developed with anti-
albumin antibodies (Fig. 3C) showed that the species with
Mrs = 360,000 and 400,000 contained albumin. These results
demonstrate that fibrinogens Nijmegen and LJmuiden contain
two fibrinogen-albumin complexes with Mrs expected for
albumin linked to LMW Fbg and HMW Fbg, respectively.
The larger species (Mr 600,000-700,000) may be dimers
Proc. Natl. Acad. Sci. USA 89 (1992)
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FIG. 3. SDS/PAGE and immunoblot analysis of purified fibrin-
ogen. Samples of fibrinogen Nijmegen (lanes 1), fibrinogen IJmuiden
(lanes 2), and normal fibrinogen (lanes 3) were electrophoresed on
2-16% polyacrylamide gradient/SDS gels and either stained with
Coomassie blue (A) or transferred to nitrocellulose and developed
with a monoclonal antibody to fibrinogen (Y18/HRP, B) or with goat
anti-albumin/HRP (C). Molecular weights are given as Mr x 10-3.
formed from HMW Fbg and LMW Fbg, or they may be
complexes of fibrinogen with other proteins.
Determination of Free Sulflhydryl Groups. The number of
sulfhydryl groups present in these fibrinogens was deter-
mined by titration of the denatured purified proteins with
DTNB (23, 24). Less than 0.05 mol of SH per mol of
fibrinogen was found with normal protein, whereas fibrino-
gen IJmuiden contained 0.18 ± 0.05 mol of SH per mol of
fibrinogen, and fibrinogen Nijmegen contained 0.13 ± 0.05
mol of SH per mol of fibrinogen. Thus, both abnormal
proteins contained new free sulfhydryl groups.
Measurement ofFibrinogen-Albumin Complexes. To detect














FIG. 4. Enzyme immunoassays for fibrinogen-albumin com-
plexes in plasma. Dose-response curves were determined for plas-
mas Nijmegen (m, A) and IJmuiden (m, B). Standard curves were
prepared by mixing normal plasma with 50%o (o), 25% (e), 15% (A),
10% (A), and 5% (a) of purified fibrinogen Nijmegen-albumin com-







0 5 10 15 20 25
FRACTION NUMBER
FIG. 5. FPLC analysis of plasma samples. Normal (e), Nijmegen
(m), and IJmuiden (A) samples were run over a Superose 12 column
and the collected fractions were analyzed by immunoassay for
fibrinogen (A) or fibrinogen-albumin complexes (B).
developed an enzyme immunoassay specific for these com-
plexes. To obtain reference standards, we isolated complexes
from purified abnormal fibrinogens by affinity chromatogra-
phy on a rabbit anti-albumin IgG Sepharose column as
described in Materials and Methods. Purified complexes
were added to normal plasma to create reference samples
with different fibrinogen/fibrinogen-albumin ratios. Dose-
response curves of the patients' plasmas were compared to
reference curves (Fig. 4). Complexes with plasma IJmuiden
were estimated as 20% of total fibrinogen (Fig.'4B) and
complexes with plasma Nijmegen were estimated as 13% of
total fibrinogen (Fig. 4A).
Measurement of Larger Fibrinogen Complexes. To measure
the concentration of larger fibrinogen complexes (Mr =
600,000-700,000), samples were separated by gel filtration
and fractions were assayed for fibrinogen (Fig. 5A) and
fibrinogen-albumin complexes (Fig. SB), as described in
Materials and Methods. Fibrinogen-albumin complexes
were present in fractions 9-12 for both abnormal plasmas. In
addition, both plasmas contained a fibrinogen crossreactive
peak at fraction 6, indicating the presence of larger fibrinogen
complexes. Analysis of the peak areas demonstrated that
these larger complexes were approximately 10% and 15% of
total fibrinogen in the IJmuiden and Nijmegen plasmas,
respectively.
DISCUSSION
We have identified the structural defect in two congenital
abnormal fibrinogens, designated IJmuiden and Nijmegen.
Both were heterozygous for a single base substitution (C -+
T) changing codons for Arg to Cys. The defect in fibrinogen
IJmuiden, BfArg14-*Cys, has also been found in fibrinogens
Christchurch II (6) and Seattle 1 (7). The defect in Nijmegen,
B344Arg-+Cys, has not been previously reported. We exam-
ined the fate of these abnormal Cys residues and found that
abnormal fibrinogens circulate as disulfide-linked complexes
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the additional cysteine introduced by the mutation and the
free sulfhydryl group present in albumin (32). Both abnormal
fibrinogens contained two complexes, presumably albumin
linked to HMW fibrinogen and to LMW fibrinogen. It is
unknown whether fibrinogen becomes linked to albumin
during or after synthesis of these proteins, for albumin and
fibrinogen are synthesized in hepatocytes. Disulfide-linked
albumin complexes have also been detected with a variant of
antithrombin III [Northwick Park, Arg393-+Cys (29)], which
is also synthesized in hepatocytes.
We also identified three larger fibrinogen complexes in
both abnormal fibrinogens. These could be disulfide-linked
fibrinogen dimers with bonds between the two forms of
fibrinogen giving three species, HMW-HMW, HMW-LMW,
and LMW-LMW dimers. C. atrox venom digestion of puri-
fied fibrinogen Umuiden demonstrated the presence of dis-
ulfide-linked BP 1-42 dimers (Mr 14,000). This product
could arise from cleavage of fibrinogen dimers, but the Mr
14,000 band is more intense than expected from the fibrino-
gen dimer species. This suggests that intramolecular disulfide
bonds between the BP3 chains of fibrinogen Umuiden are also
present, in agreement with the reports on fibrinogen
Christchurch II (6).
We did not determine whether fibrinogens IJmuiden and
Nijmegen are linked to small molecules such as cysteine, as
was reported for fibrinogen Osaka II (8), but we did find that
a substantial fraction of the mutant molecules contained free
sulfhydryl groups. Ifwe assume that halfofthe BP chains are
mutated in these heterozygous samples, then 36% of the
Umuiden mutant chains and 26% of the Nijmegen mutant
chains contain free sulfhydryls. (This also assumes that the
new cysteine is that being measured as a free sulfhydryl.)
Similarly, albumin complexes account for 40%o of the IJ-
muiden mutant chains and 26% of the Nijmegen mutant
chains, and larger fibrinogen complexes account for 20% of
the IJmuiden and 30%o of the Nijmegen mutant chains. These
forms of the altered fibrinogens complicate interpretation of
functional studies. For example, the previously described
defective tissue-type plasminogen activator binding to fibrin
Nijmegen (12) could arise either directly from the loss of an
essential residue, Bf3Arg44, or indirectly from the presence of
disulfide-linked complexes or free sulfhydryl groups.
In summary, we have used the PCR to determine the
structural defects in abnormal fibrinogens IJmuiden,
BPArg14-+Cys, and Nijmegen, BPArg44C-ys. Analysis of
the purified abnormal fibrinogens and the corresponding
plasmas demonstrated that the additional mutant cysteine
residues formed disulfide-linked complexes with albumin.
This finding severely complicates structure-function analy-
sis, whereby amino acid substitutions are associated with
altered functions of the fibrinogen molecule.
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